Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRHR | P34981 | 6/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Posatirelin SCHEMBL195247 | 1.00 | TRHR (0.68) | TRHR | |
| SCHEMBL27830909 | 0.95 | TRHR (0.66) | TRHR | |
| SCHEMBL1371608 | 0.95 | TRHR (0.66) | TRHR | |
| SCHEMBL11182741 | 0.95 | TRHR (0.66) | TRHR | |
| SCHEMBL11179550 | 0.95 | TRHR (0.66) | TRHR | |
| SCHEMBL11331704 | 0.95 | TRHR (0.66) | TRHR | |
| SCHEMBL11174568 | 0.88 | TRHR (0.70) | TRHR | |
| SCHEMBL11328954 | 0.86 | TRHR (0.54) | TRHR | |
| SCHEMBL11179368 | 0.85 | TRHR (0.66) | TRHR | |
| SCHEMBL11333599 | 0.85 | TRHR (0.54) | TRHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4386073-A | ANTIDOTES TO EFFECTS OF CERTAIN DRUGS | PATENTBUREAU DANUBIA (HU) | 1983-05-31 | — | — | US | claimed |
| US-8568997-B2 | Detection system and uses therefor | DIMERIX BIOSCIENCE PTY LTD. (AU) | 2013-10-29 | — | — | US | disclosed |
| EP-2605015-A1 | Kits for determining the interaction of a test compound with two associated receptors | Dimerix Bioscience Pty.Ltd. (AU) | 2013-06-19 | — | — | EP | disclosed |
| EP-2080012-B1 | Methods for assaying test compounds on associated receptors | DIMERIX BIOSCIENCE PTY LTD (AU) | 2013-03-20 | — | — | EP | disclosed |
| US-20130065253-A1 | DETECTION SYSTEM AND USES THEREFOR | DIMERIX BIOSCIENCE PTY LTD. (AU) | 2013-03-14 | — | — | US | disclosed |
| US-8283127-B2 | Detection system and uses therefor | DIMERIX BIOSCIENCE PTY LTD. (AU) | 2012-10-09 | — | — | US | disclosed |
| US-20100234417-A1 | THYROTROPIN RELEASING HORMONE RECEPTOR-OREXIN RECEPTOR HETERO-DIMERS/-OLIGOMERS | DIMERIX BIOSCIENCE PTY LTD. (AU) | 2010-09-16 | — | — | US | disclosed |
| US-20100021457-A1 | DETECTION SYSTEM AND USES THEREFOR | DIMERIX BIOSCIENCE PTY LTD. (AU) | 2010-01-28 | — | — | US | disclosed |
| EP-2080012-A1 | DETECTION SYSTEM AND USES THEREFOR | Dimerix Bioscience Pty.Ltd. (AU) | 2009-07-22 | — | — | EP | disclosed |
| EP-2078037-A1 | THYROTROPIN RELEASING HORMONE RECEPTOR-OREXIN RECEPTOR HETERO-DIMERS/-OLIGOMERS | Dimerix Bioscience Pty.Ltd. (AU) | 2009-07-15 | — | — | EP | disclosed |
| WO-2008055314-A1 | THYROTROPIN RELEASING HORMONE RECEPTOR-OREXIN RECEPTOR HETERO-DIMERS/-OLIGOMERS | DIMERIX BIOSCIENCE PTY LTD (AU) | 2008-05-15 | — | — | WO | disclosed |
| WO-2008055313-A1 | DETECTION SYSTEM AND USES THEREFOR | DIMERIX BIOSCIENCE PTY LTD (AU) | 2008-05-15 | — | — | WO | disclosed |
| US-20020160961-A1 | Compositions for the treatment of the catabolic state of prolonged critical illness | NOVO NORDISK A/S (DK) | 2002-10-31 | — | — | US | disclosed |
| EP-1200111-A1 | COMPOSITIONS FOR THE TREATMENT OF THE CATABOLIC STATE OF PROLONGED CRITICAL ILLNESS | NOVO NORDISK A/S (DK) | 2002-05-02 | — | — | EP | disclosed |
| WO-2000074702-A1 | COMPOSITIONS FOR THE TREATMENT OF THE CATABOLIC STATE OF PROLONGED CRITICAL ILLNESS | NOVO NORDISK A/S (DK) | 2000-12-14 | — | — | WO | disclosed |
| EP-0564193-A1 | Heteroannulation process | ELI LILLY AND COMPANY (US) | 1993-10-06 | — | — | EP | disclosed |
| US-4386073-A | ANTIDOTES TO EFFECTS OF CERTAIN DRUGS | PATENTBUREAU DANUBIA (HU) | 1983-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020160961-A1 | Compositions for the treatment of the catabolic state of prolonged critical illness | CRH, CRHBP, TRHDE | TRHR 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.